Abstract 1003P
Background
Multimodal approach, a combination of various treatment modalities, has emerged as a potential approach for treating uHCC. It is utilized to help relieve tumor burden, slow progression, and provide survival benefits to patients. However, controversies remain in using a multimodal approach in the management of uHCC, and is still debatable. This study aims to evaluate the efficacy and safety of triple combination therapy composed of Transarterial chemoembolization (TACE), TKI, and ICI compared to dual combination therapy (TACE+TKI, TKI+ICI).
Methods
Eligible studies published before March 30, 2023 were retrieved. Outcomes of interest included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and occurrence of adverse events (AEs). Literature search was done using through PubMed, Embase, and Cochrane Library. Risk of bias assessment was done using ROBINS-I tool.
Results
Thirteen retrospective studies were included representing 1005 patients with uHCC. There was low to moderate bias among the studies. Triple combination therapy was associated with a significant improvement in survival compared to dual combination therapy: median OS, pooled HR 0.46 (95% CI: 0.39-0.54, p<0.00001) and median PFS, pooled HR 0.41 (95% CI: 0.28-0.61, p<0.00001). Triple combination therapy was also associated with a significant increase in tumor response compared to dual combination therapy: ORR, pooled RR 1.76 (95% CI: 1.51-2.06, p<0.00001), and DCR, pooled RR 1.36 (95% CI 1.24-1.49, p-<0.00001). However, triple combination therapy had a higher risk of adverse events compared to dual combination therapy, pooled RR 1.49 (95% CI: 1.19, 1.86, p=0.0004). There was no significant heterogeneity found among the studies included.
Conclusions
Triple combination therapy was associated with significantly better outcomes but higher risk of adverse events than dual combination therapy in patients with uHCC so careful consideration of the risks and benefits must be done before initiating treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18